
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Paradigms (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential
Paradigm biopharmaceuticals operates in the Pharmaceutical manufacturing industry.
Paradigm biopharmaceuticals's revenue is < 1m
Paradigm biopharmaceuticals has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.